Immune Stimulation Using a Gut Microbe-Based Immunotherapy Reduces Disease Pathology and Improves Barrier Function in Ulcerative Colitis
Ho Pan Sham(BC Children's Hospital), Bruce A. Vallance(Children's & Women's Health Centre of British Columbia), Mark Bazett, Richard N. Fedorak(University of Alberta), John K. Marshall(McMaster University), Vijay Morampudi(University of Hyderabad), Jenny Chen(Johns Hopkins University), Hyungjun Yang(University of British Columbia), Momir Bosiljcic, Brian Bressler(University of British Columbia), Michelle Jones, Beryl Luk(Simon Fraser University), Jim Pankovich, Hong Yu, Simon Sutcliffe, Hal Gunn, Hong T. Law(Simon Fraser University), Shirin Kalyan(University of British Columbia)
Cited by 36
Related Papers
Vedolizumab as Induction and Maintenance Therapy for Crohn's Disease
|New England Journal of Medicine|2013|2.7k
ECCO Guidelines on Therapeutics in Crohn's Disease: Medical Treatment
|Journal of Crohn s and Colitis|2019|1.4k
ECCO Guidelines on Therapeutics in Crohn’s Disease: Surgical Treatment
|Journal of Crohn s and Colitis|2019|1.1k
A Randomized Trial of Ustekinumab, a Human Interleukin-12/23 Monoclonal Antibody, in Patients With Moderate-to-Severe Crohn's Disease
|Gastroenterology|2008|750
Treatment of Ulcerative Colitis with a Humanized Antibody to the α <sub>4</sub> β <sub>7</sub> Integrin
|New England Journal of Medicine|2005|694